240 related articles for article (PubMed ID: 31349062)
1. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
Kazdal D; Endris V; Allgäuer M; Kriegsmann M; Leichsenring J; Volckmar AL; Harms A; Kirchner M; Kriegsmann K; Neumann O; Brandt R; Talla SB; Rempel E; Ploeger C; von Winterfeld M; Christopoulos P; Merino DM; Stewart M; Allen J; Bischoff H; Meister M; Muley T; Herth F; Penzel R; Warth A; Winter H; Fröhling S; Peters S; Swanton C; Thomas M; Schirmacher P; Budczies J; Stenzinger A
J Thorac Oncol; 2019 Nov; 14(11):1935-1947. PubMed ID: 31349062
[TBL] [Abstract][Full Text] [Related]
2. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.
Jurmeister P; Vollbrecht C; Behnke A; Frost N; Arnold A; Treue D; Rückert JC; Neudecker J; Schweizer L; Klauschen F; Horst D; Hummel M; Dietel M; von Laffert M
Lung Cancer; 2019 Dec; 138():43-51. PubMed ID: 31634654
[TBL] [Abstract][Full Text] [Related]
3. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
[TBL] [Abstract][Full Text] [Related]
4. Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas.
Dietz S; Lifshitz A; Kazdal D; Harms A; Endris V; Winter H; Stenzinger A; Warth A; Sill M; Tanay A; Sültmann H
Int J Cancer; 2019 Mar; 144(5):1061-1072. PubMed ID: 30350867
[TBL] [Abstract][Full Text] [Related]
5. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
Stenzinger A; Endris V; Budczies J; Merkelbach-Bruse S; Kazdal D; Dietmaier W; Pfarr N; Siebolts U; Hummel M; Herold S; Andreas J; Zoche M; Tögel L; Rempel E; Maas J; Merino D; Stewart M; Zaoui K; Schlesner M; Glimm H; Fröhling S; Allen J; Horst D; Baretton G; Wickenhauser C; Tiemann M; Evert M; Moch H; Kirchner T; Büttner R; Schirmacher P; Jung A; Haller F; Weichert W; Dietel M
J Thorac Oncol; 2020 Jul; 15(7):1177-1189. PubMed ID: 32119917
[TBL] [Abstract][Full Text] [Related]
6. High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study.
Talvitie EM; Vilhonen H; Kurki S; Karlsson A; Orte K; Almangush A; Mohamed H; Liljeroos L; Singh Y; Leivo I; Laitinen T; Kallajoki M; Taimen P
Neoplasia; 2020 Sep; 22(9):333-342. PubMed ID: 32585428
[TBL] [Abstract][Full Text] [Related]
7. Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.
Budczies J; Kazdal D; Allgäuer M; Christopoulos P; Rempel E; Pfarr N; Weichert W; Fröhling S; Thomas M; Peters S; Endris V; Schirmacher P; Stenzinger A
Lung Cancer; 2020 Apr; 142():114-119. PubMed ID: 32143116
[TBL] [Abstract][Full Text] [Related]
8. Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow-sorting approach.
Lorber T; Andor N; Dietsche T; Perrina V; Juskevicius D; Pereira K; Greer SU; Krause A; Müller DC; Savic Prince S; Lardinois D; Barrett MT; Ruiz C; Bubendorf L
J Pathol; 2019 Feb; 247(2):199-213. PubMed ID: 30350422
[TBL] [Abstract][Full Text] [Related]
9. Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer.
Zhang N; Wu J; Yu J; Zhu H; Yang M; Li R
Clin Lung Cancer; 2020 May; 21(3):e151-e163. PubMed ID: 31734072
[TBL] [Abstract][Full Text] [Related]
10. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
11. Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.
Quy PN; Kanai M; Fukuyama K; Kou T; Kondo T; Yamamoto Y; Matsubara J; Hiroshima A; Mochizuki H; Sakuma T; Kamada M; Nakatsui M; Eso Y; Seno H; Masui T; Takaori K; Minamiguchi S; Matsumoto S; Muto M
Oncologist; 2019 Dec; 24(12):e1401-e1408. PubMed ID: 31186376
[TBL] [Abstract][Full Text] [Related]
12. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens.
Parikh K; Huether R; White K; Hoskinson D; Beaubier N; Dong H; Adjei AA; Mansfield AS
JAMA Netw Open; 2020 Feb; 3(2):e200202. PubMed ID: 32108894
[TBL] [Abstract][Full Text] [Related]
13. Optimizing panel-based tumor mutational burden (TMB) measurement.
Budczies J; Allgäuer M; Litchfield K; Rempel E; Christopoulos P; Kazdal D; Endris V; Thomas M; Fröhling S; Peters S; Swanton C; Schirmacher P; Stenzinger A
Ann Oncol; 2019 Sep; 30(9):1496-1506. PubMed ID: 31268125
[TBL] [Abstract][Full Text] [Related]
14. Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.
Alborelli I; Bratic Hench I; Chijioke O; Prince SS; Bubendorf L; Leuenberger LP; Tolnay M; Leonards K; Quagliata L; Jermann P; Matter MS
Lung Cancer; 2020 Nov; 149():84-89. PubMed ID: 32980613
[TBL] [Abstract][Full Text] [Related]
15. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.
Buchhalter I; Rempel E; Endris V; Allgäuer M; Neumann O; Volckmar AL; Kirchner M; Leichsenring J; Lier A; von Winterfeld M; Penzel R; Christopoulos P; Thomas M; Fröhling S; Schirmacher P; Budczies J; Stenzinger A
Int J Cancer; 2019 Feb; 144(4):848-858. PubMed ID: 30238975
[TBL] [Abstract][Full Text] [Related]
16. Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden.
van den Heuvel GRM; Kroeze LI; Ligtenberg MJL; Grünberg K; Jansen EAM; von Rhein D; de Voer RM; van den Heuvel MM
Respir Res; 2021 Nov; 22(1):302. PubMed ID: 34819052
[TBL] [Abstract][Full Text] [Related]
17. Tumor mutational burden on cytological samples: A pilot study.
Pepe F; Pisapia P; Gristina V; Rocco D; Micheli M; Micheli P; Iaccarino A; Tufano R; Gragnano G; Russo G; De Luca C; Sgariglia R; Nacchio M; Girolami I; Eccher A; Russo A; Troncone G; Malapelle U
Cancer Cytopathol; 2021 Jun; 129(6):460-467. PubMed ID: 33378102
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
19. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.
Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J
Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470
[TBL] [Abstract][Full Text] [Related]
20. Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma.
Nagahashi M; Sato S; Yuza K; Shimada Y; Ichikawa H; Watanabe S; Takada K; Okamoto T; Okuda S; Lyle S; Takabe K; Tsuchida M; Wakai T
J Surg Res; 2018 Oct; 230():181-185. PubMed ID: 30072189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
